Larson Financial Group’s Viridian Therapeutics VRDN Stock Holding History
Bought
Maintained
Sold
Other funds holding VRDN
KCM
Larson Financial Group's VRDN Position: Q3 2026 in Review
Larson Financial Group reduced its Viridian Therapeutics (VRDN) stake by 7.7% in Q3 2026, selling an estimated $12.8K and leaving 7,183 shares worth $148K. The position accounts for ﹤0.01% of the portfolio, ranked #1072.
Larson Financial Group first reported a position in VRDN in Q1 2025 and has held it in 6 quarters since. 235 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.
- Larson Financial Group held 7,183 shares of Viridian Therapeutics worth $148K as of Q3 2026.
- Larson Financial Group sold 599 Viridian Therapeutics shares in Q3 2026, an estimated $12.8K.
- Viridian Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q3 2026, its #1072 holding.
- Larson Financial Group first reported a position in Viridian Therapeutics in Q1 2025 and has held it in 6 quarters since.
- 235 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.
Based on Larson Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.